Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PET Measures Breast Cancer Patients Response to Therapy

By MedImaging International staff writers
Posted on 16 Jun 2009
Noninvasive imaging can measure how well patients with the most common form of breast cancer, estrogen receptor-positive type, respond to standard aromatase inhibitor therapy after only two weeks and demonstrates similar findings that more invasive needle sampling identifies, according to new findings.

Utilizing positron emission tomography (PET) scanning and a glucose analogue called fluorodeoxyglucose (FDG), a research team led by Hannah Linden, M.D. and David Mankoff, M.D., from the Seattle Cancer Care Alliance and the University of Washington (Seattle, USA), scanned 21 patients before and after two weeks of aromatase inhibitor therapy. Many of the patients also underwent a needle biopsy as a control measure to compare the two techniques.

The results--16 of the 21 patients had a greater than 20% decline in FDG values-- "paralleled perfectly” with earlier research performed by UK-based researchers who used needle biopsies to measure whether the proliferation of cancer cells was slowed by therapy, according to Dr. Linden, who is a breast cancer oncologist.

"Our findings are exciting because they suggest that we can measure a patient's response to therapy noninvasively, and PET scanning provides us simultaneous quantitative metabolic measurements at multiple tumor sites,” Dr. Linden said. "PET has the potential to be a powerful tool to help doctors make important treatment decisions in as little as two weeks instead of two or more months.”

Patients with estrogen receptor-positive cancer have remained largely unevaluated in clinical trials because they are very difficult to image, according to Dr. Linden. "Our work allowed us to study a common problem in a way that's not been done before and to help more people. More work needs to be done but in my mind this was a homerun,” Dr. Linden said.

The study's findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting, held May 29-June 2, 2009, Orlando, FL, USA.

Related Links:

University of Washington


Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Portable X-ray Unit
AJEX140H
MRI System
nanoScan MRI 3T/7T
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro

Channels

General/Advanced Imaging

view channel
CT and fused SPECT-CT images L to R of representative healthy control, pulmonary fibrosis participant & hypersensitivity pneumonitis participant (Image courtesy of SNMMI)

New SPECT/CT Method Differentiates Inflammation from Fibrosis in Interstitial Lung Disease

Interstitial lung disease (ILD) encompasses more than 200 disorders that inflame or scar the lung interstitium and can lead to progressive respiratory failure. Determining whether active inflammation is... Read more

Imaging IT

view channel
Image: Researchers develop a vision-language model trained on large-scale data to generate clinically relevant findings from chest computed tomography images through visual question answering (Ms. Maiko Nagao from Meijo University, Japan)

Interactive AI Tool Supports Explainable Lung Nodule Assessment

Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.